Rallybio Corp (RLYB) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Rallybio Corporation on January 31, 2023. The filing discloses significant changes in executive leadership, specifically the appointment of a new Chief Financial Officer (CFO) and the final departure of the former CFO.
Key Financial Metrics and Compensation
This filing does not contain financial performance data such as revenue, profit, cash flow, or debt levels. It focuses exclusively on executive compensation arrangements:
- New CFO Base Salary: $460,000 annually.
- Sign-on Bonus: $100,000.
- Target Bonus: Up to 40% of base salary.
- Equity Grant: Option to purchase 240,000 shares of common stock, vesting over four years (25% on first anniversary, then monthly).
- Severance (Standard): 12 months of base salary and health benefits upon termination without cause or for good reason.
- Severance (Change in Control): 1.5 times the sum of base salary and target bonus, plus 18 months of health benefits and full acceleration of time-based equity.
- Former CFO Departure: Accelerated vesting of 75,000 shares of restricted common stock for Jeffrey M. Fryer.
Material Changes
The primary material change is the transition of the Chief Financial Officer role:
- Appointment: Jonathan I. Lieber was appointed CFO and Treasurer, effective February 1, 2023.
- Departure: Jeffrey M. Fryer, Co-Founder and former CFO, will depart the company on February 15, 2023, following a transition period.
Outlook, Risks, and Contingencies
The filing outlines specific contingencies regarding executive severance and non-compete agreements:
- Non-Compete: Mr. Lieber is restricted from competing with Rallybio or soliciting its customers and employees for one year following termination.
- Release Requirement: Severance payments are conditioned on the executive signing a release of claims in favor of the company.
- Change in Control: Enhanced severance and equity acceleration apply if termination occurs within 12 months of a change in control.
Investor Verification Checklist
- Verify the exact closing price of Rallybio common stock on the grant date to determine the exercise price for Mr. Lieber's 240,000 stock options.
- Review the full Employment Agreement and Fryer Separation Agreement when filed as exhibits to the Form 10-K for the fiscal year ending December 31, 2022.
- Confirm the impact of the leadership transition on the company's ongoing capital raising activities and investor relations strategy.
- Monitor the vesting schedule of the 75,000 shares accelerated for the departing CFO to assess immediate dilution effects.